A106
unprotected. Lack of proper knowledge and casual attitude for vaccina-
tion may contribute to noncompliance.
IN-4
Role of stronger neo-minophagen-C in chronic hepatitis B infection
S Sakthi Dasan, T Ramesh, S S Sakthi Gnanavel, K Anbarasan, N
Dinakaran
C. R. R. I, and Department of Gastroenterology, Melmaruvathur
Adhiparasakthi Institute of Medical Sciences and Research,
Melmaruvathur, Kancheepuram District, Tamilnadu 603 319, India
Background: Inspite of great in depth knowledge in to the
etiopathogenesis of chronic hepatitis B infection, many treatment trails
already carried out, an universally acceptable safe and effective short-
term therapy still remains elusive. Stronger Neo-Minophagen-C
(SNMC) a herbal medicine which contains Glycyrrhizin 0.2 %, Cysteine
0.1 %, Glycin 2.0 % an aqueous extract of the licorice root is used for
patients with chronic hepatitis B infection for 6 weeks period to study its
efficacy and safety.
Aim: To evaluate the short-term efficacy and safety of injection Stronger
Neo-Minophagen C (SNMC) in chronic hepatitis B infection.
Methodology: Forty-four patients with chronic hepatitis B infection to
receive either injection SNMC 100 mL normal saline intravenously as
control study 1:1 ratio daily for a period of 6 weeks after clinical assess-
ment, basic biochemical, hematological and liver function test. They are
periodically assessed every 2 weeks interval. Inclusion criteria: patients
aged between 30 and 65 years of either sex with markers of chronic
hepatitis B infection with compensatory or decompensatory liver status.
Exclusion criteria: previously treated for hepatitis, alcoholic liver disease,
hepatocellular carcinoma, metabolic syndrome, comoribund condition,
patients on hepatotoxic drugs.
Results: Overall significant clinical improvement observed in SNMC group
68 % compared to 31 % in placebo group. Promising decrease in ALT and
AST level 63 %in SNMC group compared to 24 % in placebo group.
Conclusion: SNMC therapy in chronic B hepatitis is effective and well
tolerated.
IN-5
Vitamin D supplementation in patients with nonalcoholic fatty liver
disease - A randomized controlled trial
Mallikarjun Sakpal, Manu Mehta, Ajay Duseja, Sanjay Bhadada, Ashim
Das, Radha K Dhiman, Yogesh K Chawla
Departments of Hepatology, Endocrinology and Histopathology, Post-
graduate Institute of Medical Education and Research, Chandigarh 160
012, India
Introduction: Deficiency of vitamin D may be related to the pathogenesis
of nonalcoholic fatty liver disease (NAFLD).
Aim: Aim of the present study was to evaluate the affect of vitamin D
supplementation in patients with NAFLD.
Methodology: Eighty-one consecutive patients with NAFLD with normal
or raised serum liver enzymes (AST and ALT) and with vitamin D defi-
ciency were randomized in two groups prospectively. Group 1 (n=51)
received lifestyle modifications and single injection of vitamin D (6 lac
units) given intramuscularly [standard medical treatment (SMT)+vitamin
D). Group 2 (n=30) received only life style modifications as treatment
(SMT) for 6 months in the form of regular exercise with calorie restriction
and weight reduction in those with overweight/obesity.
Indian J Gastroenterol (November 2015) 34(Suppl 1):A105–A110
Results: After 6 months, a significant improvement in serum levels
of AST and ALT was observed in SMT+vitamin D group when
compared to SMT group. Mean insulin levels and HOMA-IR
remained unchanged at 6 months in SMT + vitamin D group
whereas there was a significant increase in mean insulin levels
and HOMA-IR in SMT group. In the SMT +vitamin D group,
there was a significant increase in the mean serum levels of
adiponectin (p=0.018) compared to the baseline levels; TNFα ±
levels also decreased from the baseline levels but the change was
not statistically significant (p=0.166).
Conclusions: In comparison to patients with NAFLD managed only
with lifestyle modifications, patients given vitamin D in addition
to lifestyle modifications causes significant improvement in serum
levels of AST and ALT and significant increase in serum
adiponectin levels.
IN-6
Effect of moderate intensity exercise for 6 months on nonalcoholic
fatty liver disease and its risk factors
Preetam Nath, Manas Kumar Panigrahi, Manoj Kumar Sahu, Ranjan
Kumar Sahoo, Jimmy Narayan, Arun Kumar Patnaik, Anjan Jena,
Ananya Apurba Patra, Shivaram Prasad Singh
Department of Gastroenterology, S C B Medical College, Dock
Road, Manglabag, Cuttack, Odisha 753 007, Department of Gas-
troenterology and Radiodiagnosis, I M S and S U M Hospital,
Bhubaneswar, Biju Pattnaik State Police Academy Dispensary,
Bhubaneswar, Department of Radiodiagnosis, Kalinga Institute of
Medical Sciences, KIIT Road, Chandaka Industrial Estate, Patia,
Bhubaneshwar, Odisha 751 024, India
Introduction: Lifestyle (exercise and dietary) modification is the
mainstay of treatment for nonalcoholic fatty liver disease
(NAFLD). However, there is paucity of data on physical activity
in management of NAFLD especially regarding requisite duration
and intensity of exercise.
Aim: To study the effect of moderate intensity exercise in NAFLD
patients.
Methods: The study was performed in Department of Gastroenter-
ology in S C B Medical College, Cuttack and Biju Pattnaik State
Police Academy, Bhubaneswar. The subjects consisted of police
recruits (n=32) for a 6 month physical training course (241 K
calorie, 3.6 MET). NAFLD was diagnosed by ultrasonography
of all trainees. Participants who had secondary causes of steatosis
were excluded. All subjects were evaluated for metabolic syn-
drome by anthropometry (weight, height, BMI, waist circumfer-
ence), blood pressure, biochemical investigations (blood-glucose,
liver function test, lipid-profile, serum insulin) and subjected to
transabdominal ultrasonography before and after 6 months’ phys-
ical training and the results were compared.
Results: There was a significant reduction in BMI (27.0± 2.1 to
26.8±2.0, p=0.001), fasting (106.7±21.6 to 85.8±19.0, p<0.001)
and 2 h post glucose blood-glucose (152.9±62.6 to 120.1±40.8,
p=0.086), triglyceride (167.5±56.7 to 124.6±63.5, p=0.017), total
(216.8±29.2 to 196.7±26.6, p=0.037) and LDL (134.6± 21.4 to
130.5±21.9, p=0.010) cholesterol, serum AST (39.3±32.2 to 30.9
± 11.4, p < 0.001), ALT (56.6 ± 28.7 to 33.0 ± 11.3, p < 0.001),
HOMA-IR (2.63 ± 2.66 to 1.70 ± 2.59, p < 0.001). The hepatic
steatosis regressed in 7 of 10 NAFLD subjects.
Conclusion: Six months moderate intensity physical activity causes sig-
nificant improvement in BMI, serum triglyceride, cholesterol, serum
transaminases, HOMA IR and regression of fatty change in patients with
NAFLD.